Intec Pharma’s (NTEC) “Hold” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their hold rating on shares of Intec Pharma (NASDAQ:NTEC) in a research report released on Monday morning, TipRanks reports.

NTEC has been the subject of a number of other reports. Zacks Investment Research raised shares of Intec Pharma from a hold rating to a buy rating and set a $0.75 price objective for the company in a report on Wednesday, October 16th. Roth Capital lowered Intec Pharma from a buy rating to a neutral rating and cut their price objective for the company from $10.00 to $1.00 in a research report on Friday, October 11th. ValuEngine downgraded Intec Pharma from a buy rating to a hold rating in a research report on Friday, November 1st. Finally, LADENBURG THALM/SH SH reissued a hold rating on shares of Intec Pharma in a research report on Monday, August 12th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $9.96.

NASDAQ NTEC opened at $0.51 on Monday. The stock’s 50-day moving average price is $0.63 and its 200-day moving average price is $1.97. The company has a market capitalization of $16.29 million, a P/E ratio of -0.36 and a beta of -0.13. Intec Pharma has a 52 week low of $0.41 and a 52 week high of $9.25.

Intec Pharma (NASDAQ:NTEC) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.10). On average, analysts forecast that Intec Pharma will post -0.92 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. acquired a new position in shares of Intec Pharma in the 2nd quarter valued at $125,000. Morgan Stanley boosted its holdings in shares of Intec Pharma by 38.4% in the 2nd quarter. Morgan Stanley now owns 81,931 shares of the biotechnology company’s stock valued at $356,000 after acquiring an additional 22,715 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Intec Pharma in the third quarter worth $96,000. Renaissance Technologies LLC purchased a new position in shares of Intec Pharma during the 2nd quarter valued at about $593,000. Finally, River & Mercantile Asset Management LLP acquired a new position in shares of Intec Pharma in the 2nd quarter valued at about $1,230,000. 17.21% of the stock is owned by institutional investors and hedge funds.

About Intec Pharma

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

See Also: The role of implied volatility with call option volume

Analyst Recommendations for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.